The Alberta RWE Consortium is pleased to announce that the first project that will be supported by the Consortium is on the topic of biologics/biosimilars. The deliverables of this project will support Alberta Health with managing the translation, implementation, and monitoring of policy developed via a collaborative pan-Canadian process managed by the pCPA. The project will enable Alberta to realize the expected benefits from the introduction of biosimilars to the health system and the patients it serves. Specifically, it will:
- support Alberta Health and other stakeholders with pan-Canadian policy direction and principle interpretation/adaptation to the Alberta context in order to inform Alberta biosimilar strategy;
- provide an implementation framework and supporting resources to assist patients and physicians to utilize biosimilars as intended by policy; and
- prospectively build an evidence base to inform policy, and provide a monitoring and reporting service regarding outcomes achieved with biosimilars to inform clinical decision-making.
Further information about how stakeholder input will inform this project will be shared when available.